| P2093 | author name string | Stanley C Jordan | |
| | William M Baldwin | |
| | Mel Berger | |
| P2860 | cites work | Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss | Q82554497 |
| | Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA) | Q83101436 |
| | The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation | Q83358090 |
| | Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes | Q83366581 |
| | Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation | Q84070569 |
| | Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy | Q84348763 |
| | Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 |
| | Immunologic challenges in small bowel transplantation | Q85532102 |
| | Circulating donor-specific anti-human leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy | Q85946550 |
| | Chronic antibody-mediated rejection: new diagnostic tools - clinical significance of C4d deposition and improved detection and characterization of human leucocyte antigen antibodies | Q86421426 |
| | C1-esterase-inhibitor for primary graft dysfunction in lung transplantation | Q87365655 |
| | Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients | Q87763662 |
| | Chronic immune-mediated reaction syndrome as the cause of late graft mortality in living-donor liver transplantation for primary biliary cirrhosis | Q87895320 |
| | Determinants of C1q binding in the single antigen bead assay | Q88058283 |
| | The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection | Q26862195 |
| | Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms | Q27314948 |
| | Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis | Q28084366 |
| | Complement. First of two parts | Q28210663 |
| | Complement. Second of two parts | Q28211878 |
| | ABO incompatible renal transplants: Good or bad? | Q28236829 |
| | OPTN/SRTR 2011 Annual Data Report: kidney | Q30581465 |
| | C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage | Q31132259 |
| | Local and remote ischemia-reperfusion injury is mitigated in mice overexpressing human C1 inhibitor | Q33203441 |
| | Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. | Q33232995 |
| | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial | Q33584895 |
| | Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage | Q33745120 |
| | Investigations on the C1q–Calreticulin–Phosphatidylserine Interactions Yield New Insights into Apoptotic Cell Recognition | Q59343981 |
| | Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis | Q68856319 |
| | Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock | Q74463712 |
| | Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection | Q74644326 |
| | Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver | Q77332273 |
| | C1-esterase inhibitor reduces reperfusion injury after lung transplantation | Q77611768 |
| | Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation | Q78077769 |
| | C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion | Q79436728 |
| | Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome | Q79820431 |
| | C3d and C4d deposition early after lung transplantation | Q81532409 |
| | Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers | Q34342506 |
| | Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation | Q34532579 |
| | Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. | Q34659840 |
| | Diagnosis and management of antibody-mediated rejection: current status and novel approaches | Q34841849 |
| | Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses. | Q35225843 |
| | Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention | Q35236103 |
| | De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients | Q35535173 |
| | Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com | Q35565781 |
| | Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts | Q35790552 |
| | Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex | Q36123185 |
| | Antibodies to K-α 1 tubulin and collagen V are associated with chronic rejection after lung transplantation | Q36131035 |
| | Rational clinical trial design for antibody mediated renal allograft injury. | Q36173541 |
| | Some properties of an esterase derived from preparations of the first component of complement | Q36263558 |
| | Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement | Q36366602 |
| | Structure and function of C1-inhibitor | Q36645169 |
| | Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients | Q36772957 |
| | Selectin inhibitors and their proposed role in ischemia and reperfusion | Q36799791 |
| | C1 inhibitor: biologic activities that are independent of protease inhibition | Q36838407 |
| | Antibody mediated rejection: update 2006. | Q36910384 |
| | Chronic alloantibody mediated rejection | Q37058050 |
| | The role of the complement system in acute kidney injury | Q37275159 |
| | Properdin: emerging roles of a pattern-recognition molecule. | Q37641361 |
| | Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection | Q37654098 |
| | Primary graft dysfunction. | Q37670609 |
| | Advances in diagnosing and managing antibody-mediated rejection | Q37676032 |
| | Therapeutic Complement Inhibition: New Developments | Q37791964 |
| | Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy | Q37796385 |
| | Role of complement and perspectives for intervention in ischemia-reperfusion damage. | Q37831329 |
| | The innate immune system in transplantation. | Q37896918 |
| | Prevention and treatment of alloantibody-mediated kidney transplant rejection | Q37914943 |
| | The impact of donor-specific anti-HLA antibodies on late kidney allograft failure | Q38003049 |
| | Phenotypes of antibody-mediated rejection in organ transplants | Q38005448 |
| | Regulation of humoral immunity by complement | Q38037801 |
| | The complement system in ischemia-reperfusion injuries | Q38042217 |
| | Lung ischemia reperfusion injury: a bench-to-bedside review | Q38050047 |
| | Role of complement and perspectives for intervention in transplantation | Q38062698 |
| | Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation | Q38069292 |
| | Complement system activation in cardiac and skeletal muscle pathology: friend or foe? | Q38080872 |
| | Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation | Q38097126 |
| | Anaphylatoxins in organ transplantation | Q38110668 |
| | Eculizumab in renal transplantation. | Q38112915 |
| | Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance | Q38120396 |
| | Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. | Q38169496 |
| | Ischemia/reperfusion injury: effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. | Q38175226 |
| | Complement as a multifaceted modulator of kidney transplant injury | Q38217273 |
| | Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy | Q38218005 |
| | Complement modulation in solid-organ transplantation. | Q38226479 |
| | Humoral immunity and complement effector mechanisms after lung transplantation | Q38246582 |
| | Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection | Q38282840 |
| | Blood Vessels in Allotransplantation | Q38390676 |
| | Kidney transplantation in highly sensitized patients | Q38455229 |
| | Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment | Q38541350 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Role of alloimmunity and autoimmunity in allograft rejection | Q41226453 |
| | Which pathways trigger the role of complement in ischaemia/reperfusion injury? | Q41438903 |
| | Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure | Q42171636 |
| | How to define initial poor graft function after liver transplantation? - a new functional definition by the LiMAx test | Q43073397 |
| | A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. | Q43276888 |
| | The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes | Q44174433 |
| | Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury | Q44707321 |
| | Human C1 inhibitor attenuates liver ischemia-reperfusion injury and promotes liver regeneration | Q45244515 |
| | Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 |
| | A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. | Q45932199 |
| | Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 |
| | The effect of C1 inhibitor on intestinal ischemia and reperfusion injury | Q46372780 |
| | Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma | Q46892395 |
| | A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings | Q47858437 |
| | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 |
| | Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria. | Q50516657 |
| | A direct role for C1 inhibitor in regulation of leukocyte adhesion. | Q51817466 |
| | The role of polymorphonuclear leucocytes in the pulmonary dysfunction induced by complement activation. | Q54455112 |
| | C1 inhibitor, a multi-functional serine protease inhibitor | Q56772868 |
| | Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement | Q58523732 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Serpin family G member 1 | Q416510 |
| P304 | page(s) | 1415-1424 | |
| P577 | publication date | 2015-11-23 | |
| | 2016-07-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Potential Roles for C1 Inhibitor in Transplantation | |
| P478 | volume | 100 | |